Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Marks

Showing results (641-650 of 683) with videos related to

Pageof 69
Sort By:
Bone Marrow Transplantation|January 5, 2016
The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysisK M Williams, K W Ahn, M Chen, et al.
Cancer|November 11, 2017
Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphomaRegina M Myers, Brian T Hill, Bronwen E Shaw, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remissionMartin S Tallman, Waleska S Pérez, Hillard M Lazarus, et al.
Leukemia|August 31, 2013
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual diseaseV Bachanova, D I Marks, M-J Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 4, 2019
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell TransplantationBetty K Hamilton, Ying Liu, Michael T Hemmer, et al.
Blood|April 25, 2021
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALLElisabeth Paietta, Kathryn G Roberts, Victoria Wang, et al.
Bone Marrow Transplantation|August 4, 2015
A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphomaP Satwani, K W Ahn, J Carreras, et al.
Blood Advances|May 10, 2018
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplantsAnita J Kumar, Soyoung Kim, Michael T Hemmer, et al.
Blood|September 26, 2013
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBIEdward A Copelan, Betty K Hamilton, Belinda Avalos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 22, 2014
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiationEdward A Copelan, Belinda R Avalos, Kwang Woo Ahn, et al.
Pageof 69

Showing results (641-650 of 683) with videos related to

Sort By:
Pageof 69
Bone Marrow Transplantation|January 5, 2016
The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysisK M Williams, K W Ahn, M Chen, et al.
Cancer|November 11, 2017
Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphomaRegina M Myers, Brian T Hill, Bronwen E Shaw, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remissionMartin S Tallman, Waleska S Pérez, Hillard M Lazarus, et al.
Leukemia|August 31, 2013
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual diseaseV Bachanova, D I Marks, M-J Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 4, 2019
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell TransplantationBetty K Hamilton, Ying Liu, Michael T Hemmer, et al.
Blood|April 25, 2021
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALLElisabeth Paietta, Kathryn G Roberts, Victoria Wang, et al.
Bone Marrow Transplantation|August 4, 2015
A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphomaP Satwani, K W Ahn, J Carreras, et al.
Blood Advances|May 10, 2018
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplantsAnita J Kumar, Soyoung Kim, Michael T Hemmer, et al.
Blood|September 26, 2013
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBIEdward A Copelan, Betty K Hamilton, Belinda Avalos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 22, 2014
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiationEdward A Copelan, Belinda R Avalos, Kwang Woo Ahn, et al.
Pageof 69